as on October 29, 2025 at 7:35 pm IST
Day's Low
Day's High
0.90%
Downside
1.42%
Upside
52 Week's Low
52 Week's High
42.38%
Downside
5.66%
Upside
Check Ascendis Pharma A/s market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$12.3B
EPS (TTM)
-2.2124
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-248.6M
Revenue (TTM)
490.7M
Profit Margin
-55.25%
Return On Equity TTM
-818.43%
Compare market cap, revenue, PE, and other key metrics of Ascendis Pharma A/s with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $12.3B | 25.55% | NA | -55.25% | |
| BUY | $62.7B | 285.91% | -505.15 | -12.96% | |
| NA | $36.5B | NA | NA | -3.89% | |
| BUY | $108.0B | 104.04% | 29.95 | 31.86% | |
| BUY | $62.0B | 17.76% | 14.75 | 31.37% |
The Ascendis Pharma A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Ascendis Pharma A/s investment value today
Current value as on today
₹1,66,653
Returns
₹66,653
(+66.65%)
Returns from Ascendis Pharma A/s Stock
₹61,592 (+61.59%)
Dollar Returns*
₹5,061 (+5.06%)
Based on 20 analysts
80.00%
Buy
20.00%
Hold
0.00%
Sell
Based on 20 analysts, 80% of analysts recommend a 'BUY' rating for Ascendis Pharma A/s. Average target price of $252.33
Get share price movements and forecasts by analysts on Ascendis Pharma A/s.
What analysts predicted
18.82%UPSIDE
Target Price
$252.33
Current Price
$204.85
Analyzed by
20 Analysts
Target
$252.33
Ascendis Pharma A/s target price $252.33, a slight upside of 18.82% compared to current price of $204.85. According to 20 analysts rating.
Search interest for Ascendis Pharma A/s Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
![]()
Netprofit is up for the last 2 quarters, -94.62M → -38.85M (in $), with an average increase of 143.5% per quarter
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 100.95M → 158.04M (in $), with an average increase of 36.1% per quarter
Price Rise
![]()
In the last 3 months, ASND stock has moved up by 26.1%
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 132.7% return, outperforming this stock by 45.5%
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.2% return, outperforming this stock by 4.8%
| Organisation | Ascendis Pharma A/s |
| Headquarters | Tuborg Boulevard 12, Hellerup, Denmark, 2900 |
| Industry | Health Technology |
| CEO | Mr. Jan Moller Mikkelsen |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board |
Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board |
Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director |
Ms. Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board |
Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development |
Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology |
Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology |
Ms. Sherrie Glass | Chief Business Officer |
Ascendis Pharma A/s share price today is $204.85 as on . Ascendis Pharma A/s share today touched a day high of $207.75 and a low of $203.01.
Ascendis Pharma A/s share touched a 52 week high of $216.45 on and a 52 week low of $118.03 on . Ascendis Pharma A/s stock price today i.e. is trending at $204.85,which is 5.36% down from its 52 week high and 73.56% up from its 52 week low.
Ascendis Pharma A/s market capitalisation is $0.01T as on .
Indian investors can start investing in Ascendis Pharma A/s (ASND) shares with as little as ₹88.178 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.78 in Ascendis Pharma A/s stock (as per the Rupee-Dollar exchange rate as on ).
Based on Ascendis Pharma A/s share’s latest price of $204.85 as on October 29, 2025 at 7:35 pm IST, you will get 0.0488 shares of Ascendis Pharma A/s. Learn more about
fractional shares .
Ascendis Pharma A/s stock has given 25.55% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?